Physicochemical and biological studies of a new erythromycin derivate - erythromycin folate

Article English OPEN
Manna, P.K.; Kumaran, V.; Mohanta, G.P.;
(2005)
  • Publisher: Universidad de Granada, Facultad de Farmacia
  • Subject: Parámetros farmacocinético | Erythromycin folate | Actividad antimicrobiana in vitro | Pharmacokinetic parameters | Folato de eritromicina | In vitro antimicrobial activity | In vivo serum concentration | Concentración sérica in vivo
Se preparó un derivado nuevo de la eritromicina, el folato de eritromicina, y se evaluaron sus propiedades fisicoquímicas y biológicas. El derivado presenta una buena solubilidad en metanol, etanol y propileno glicol. Los valores de los coeficientes de partición, ... View more
  • References (24)
    24 references, page 1 of 3

    diante la fórmula siguiente: 1. British National Formulary 46 British Medical Association, Royal Pharmaceutical Society of Great Britain, Pharmaceutical

    Press, 2003; 274 - 275 2. American Society of Health System Pharmacist, American Hospital Formulary Service, MD, America, 2001; 3316 - 3318 3. Mycek MJ, Harvey RA, Champe PC. in: Pharmacology. Harvey RA, Champe PC. ed., Lipincott Williams and Wilkins,

    New York, 2000; 317 - 321. 4. Haslet C, Edwin R, Chilvers R, John A, Hunter A, Boon NA. in: Principles and Practice of Medicine. Davidson, ed.,

    Churchill Livingstone, London, 2000; 344. 5. Laurence DR, Bennet AN, Brown NJ. in; Clinical Pharmacology. D. R. Laurence ed., Churchill Livingstone, 1997; 208

    - 209. 6. Garrod LP, Lambert HP, Grady FO. in; Antibiotics and Chemotherapy. 7. Bray and Stephens, Preparation of erythromycin estolate (ester salt). U.S. Patent 3,000,874 (1961 to Lilly Laboratories,

    U.S.A). 8. Walasek OF, Preparation of erythromycin stearate, (salt). U.S. Patent 2,881,163 (1959 to Abbott, Laboratories, U.S.A). 9. Shepher, Preparation of erythromycin glucoheptonate (salt). U.S. Patent 2,852,429 (1958 to Lilly Laboratories, U.S.A). 10. Hoffhine, Preparation of erythromycin lactobionate (salt). U.S. Patent 2,761,859 (1956 to Abbott, Laboratories, U.S.A). 11. Stephens VC, Preparation of erythromycin propionate. U.S. Patent 2,993,833 (1961 to Lilly, Laboratories, U.S.A). 12. Morvolla MLA, Preparation of erythromycin acistrate (ester prodrug). Belgian Patent, 901,411 (1985 to Orion Yhtyma

    Oy). 13. Honkanen EJ, Preparation of erythromycin acistrate (ester prodrug). U.S. Patent 4,599,326 (1986 to Orion Ohiama). 14. Chun AHC, Seitz JA. Drug Bioavailability Information and its Utility. J. Am. Pharm. Ass. 1974; 14: 407 - 414. 15. Chun AHC, Seitz JA, Pharmacokinetics and Biological Availability of Erythromycin. Infection. 1977; 5 (suppl): 14 -

    22. 16. Mathur CE, Austin KC, Philpot CR, McDonald PJ. Absorption and oral bioavailability of erythromycin. Br. J. Clin.

    Pharmac. 1981; 12: 131 - 140. 17. Czeizel AE, Dudas I. Prevention of first occurrence of neural tube defects by preconceptional vitamin supplementation.

    N Engl. J. Med. 1992; 327: 1831 - 1835. 18. Bery RJ, Li Z, Errickson J. Prevention of neural - tube defects with folic acid in China. N Engl. J. Med. 1999; 341:

  • Related Organizations (1)
  • Metrics
Share - Bookmark